Nestle Sells Peanut-Allergy Treatment Business to Stallergenes Greer

Nestle said it has sold its Palforzia peanut-allergy treatment business to biopharmaceutical company Stallergenes Greer.

The Swiss consumer-goods company said Monday that it will receive milestone payments and royalties from Stallergenes Greer. The deal was closed upon signing, Nestle said. The sale allows Nestle's health-science operations to focus on its core strengths and key growth drivers, the unit's Chief Executive Greg Behar said.

Nestle last year said that it would conduct a strategic review of Palforzia after a slower-than-expected adoption by patients and healthcare professionals.

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Nestle divests peanut allergy business Palforzia By ReutersNestle divests peanut allergy business Palforzia
La source: Investingcom - 🏆 450. / 53 Lire la suite »

Nestle divests peanut allergy business PalforziaNestle has divested its peanut allergy treatment business Palforzia, the Swiss food company said on Monday, following its strategic review of the division.
La source: Reuters - 🏆 2. / 97 Lire la suite »